Jennison Associates LLC Has $141.40 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Jennison Associates LLC decreased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 10.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,237,430 shares of the company’s stock after selling 145,701 shares during the period. Jennison Associates LLC’s holdings in Vaxcyte were worth $141,401,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $1,189,000. Meeder Asset Management Inc. boosted its position in shares of Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the period. Pathstone Holdings LLC raised its stake in shares of Vaxcyte by 7.6% in the third quarter. Pathstone Holdings LLC now owns 30,527 shares of the company’s stock valued at $3,488,000 after purchasing an additional 2,154 shares in the last quarter. Natixis Advisors LLC raised its stake in shares of Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after purchasing an additional 8,606 shares in the last quarter. Finally, CIBC Asset Management Inc raised its stake in shares of Vaxcyte by 3.6% in the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock valued at $358,000 after purchasing an additional 110 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Bank of America lifted their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Leerink Partners boosted their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $147.50.

Insider Transactions at Vaxcyte

In other news, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This represents a 8.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 117,464 shares of company stock valued at $12,640,276. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Stock Up 0.7 %

Shares of Vaxcyte stock opened at $87.08 on Wednesday. Vaxcyte, Inc. has a 12-month low of $48.24 and a 12-month high of $121.06. The business’s 50 day moving average is $109.51 and its 200-day moving average is $89.13. The stock has a market cap of $10.85 billion, a P/E ratio of -18.93 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the firm posted ($0.91) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.